Shanghai Starry Pharmaceutical Co., Ltd.,

• Categories:Subsidiary
• Time of issue:2019-12-13 00:00:00
• Views:0

Information

 

　　Shanghai Starry Pharmaceutical Co., Ltd., founded in June 2012, is a wholly-owned subsidiary of Starry. Currently, it is mainly engaged in research and development and production of nonionic contrast agent diagnostic pharmaceutical preparations. With registered capital of RMB 100 million and covering an area of 5 hectares, the company has 70,000 square meters of factory buildings and total assets of more than RMB 500 million.

 

　　At present, the company has four production lines, namely, a large-capacity injection production line, a small-capacity injection production line, a cream (hormone) production line, and a cream & gel production line. With the registration certificates for four varieties and eight specifications including miconazole nitrate cream, miconazole clobetasol cream, lincomycin lidocaine gel, and compound dexamethasone acetate cream, the company has obtained the drug production license, ointment drug registration certificate and GMP certificate.

 

　　The company is in the most critical part of Starry Pharm’s strategic layout in the whole industry chain of contrast agents. It plans to launch a variety of nonionic contrast agent products in the market in the next few years. At present, there are 3 varieties and 4 specifications of iohexol, iodophor and iodixanol under review and approval by China Food and Drug Administration. At the same time, it also plans on registration application in overseas markets. In the near future, Shanghai Starry Pharmaceutical Co., Ltd. will fill in the gap of Starry Pharm in the pharmaceutical industry chain and assist it in completing the industrial transformation from bulk drugs to preparations.